How do you follow/manage patients with metastatic prostate cancer with undetectable PSA and castration-sensitive but active disease on PSMA PET?  

Summary: This is a challenging clinical scenario, and one in which I think there is currently a lot of practice variability. In such cases, I would not jump to action immediately, and I would first try to obtain some additional information. This would include repeat PSA for confirmation as well as f...

I’m not sure there is any data to guide us in this situation. Until new data are available, I suggest we adhere to the principle of “first, do no harm” and simply monitor. I obtain PSMA PET periodically (q6 months if no change on PSA q3 months) to evaluate for progression. If there...